Abstract | BACKGROUND: PATIENTS AND METHODS: We conducted a multicenter open-labeled randomized phase II trial in chemo-naïve patients with advanced HCC with Child-Pugh scores of 5-7. Eligible patients were randomly assigned 2:1 to receive SorCDDP ( sorafenib: 400 mg bid; cisplatin: 65 mg/m2, day 1, every 4-6 weeks) or Sor (400 mg bid). The primary end point was overall survival. RESULTS: A total of 108 patients were randomized (Sor, n = 42; SorCDDP, n = 66). The median survival in the Sor and SorCDDP arms were 8.7 and 10.6 months, respectively [stratified hazard ratio (95% confidence interval), 0.60 (0.38-0.96), P = 0.031]. The median time to progression and the response rate were, respectively, 2.8 months and 7.3% in the Sor arm and 3.1 months and 21.7% in the SorCDDP arm. The adverse events were more frequent in the SorCDDP arm than in the Sor arm, but well-tolerated. CONCLUSION: SorCDDP yielded favorable overall survival when compared with Sor in patients with advanced HCC. CLINICAL TRIAL REGISTRATION: UMIN-CTR (http://www.umin.ac.jp/ctr/index-j.htm), identification number: UMIN000005703.
|
Authors | M Ikeda, S Shimizu, T Sato, M Morimoto, Y Kojima, Y Inaba, A Hagihara, M Kudo, S Nakamori, S Kaneko, R Sugimoto, T Tahara, T Ohmura, K Yasui, K Sato, H Ishii, J Furuse, T Okusaka |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 27
Issue 11
Pg. 2090-2096
(11 2016)
ISSN: 1569-8041 [Electronic] England |
PMID | 27573564
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
|
Copyright | © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. |
Chemical References |
- Phenylurea Compounds
- Niacinamide
- Sorafenib
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Carcinoma, Hepatocellular
(drug therapy, pathology)
- Cisplatin
(administration & dosage)
- Disease-Free Survival
- Female
- Humans
- Kaplan-Meier Estimate
- Liver Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Niacinamide
(administration & dosage, analogs & derivatives)
- Phenylurea Compounds
(administration & dosage)
- Sorafenib
- Treatment Outcome
|